Search research articles
Contact Us
Filters
Showing results (431-440 of 471) with videos related to
Page
of 48
Sort By:
Endocrine-Related Cancer
|
October 5, 2017
<i>TERT</i> structural rearrangements in metastatic pheochromocytomas
Trisha Dwight, Aidan Flynn, Kaushalya Amarasinghe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet, Shahneen Sandhu, Amir Iravani, et al.
Journal of Medicinal Chemistry
|
July 16, 2015
Synthesis and in Vivo Evaluation of [123I]Melanin-Targeted Agents
Maxine P Roberts, Vu Nguyen, Mark E Ashford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Malik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.
Blood
|
April 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
Sasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, et al.
Cancer Discovery
|
June 30, 2022
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Peter Savas, Louisa L Lo, Stephen J Luen, et al.
Annals of Neurology
|
January 5, 2019
Metabolic patterns and seizure outcomes following anterior temporal lobectomy
Varduhi Cahill, Benjamin Sinclair, Charles B Malpas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 10, 2013
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
Karen E Sheppard, Carleen Cullinane, Katherine M Hannan, et al.
The Journal of Clinical Investigation
|
January 5, 2012
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
Kathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, et al.
Journal of Neuroendocrinology
|
December 14, 2023
Use and perceived utility of [<sup>18</sup> F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022
Valentina Ambrosini, Martyn Caplin, Justo P Castaño, et al.
Page
of 48
Search research articles
Search
Showing results (431-440 of 471) with videos related to
Sort By:
Page
of 48
Endocrine-Related Cancer
|
October 5, 2017
<i>TERT</i> structural rearrangements in metastatic pheochromocytomas
Trisha Dwight, Aidan Flynn, Kaushalya Amarasinghe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of <sup>177</sup>Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet, Shahneen Sandhu, Amir Iravani, et al.
Journal of Medicinal Chemistry
|
July 16, 2015
Synthesis and in Vivo Evaluation of [123I]Melanin-Targeted Agents
Maxine P Roberts, Vu Nguyen, Mark E Ashford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Malik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.
Blood
|
April 25, 2024
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
Sasanka M Handunnetti, Mary Ann Anderson, Kate Burbury, et al.
Cancer Discovery
|
June 30, 2022
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Peter Savas, Louisa L Lo, Stephen J Luen, et al.
Annals of Neurology
|
January 5, 2019
Metabolic patterns and seizure outcomes following anterior temporal lobectomy
Varduhi Cahill, Benjamin Sinclair, Charles B Malpas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 10, 2013
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
Karen E Sheppard, Carleen Cullinane, Katherine M Hannan, et al.
The Journal of Clinical Investigation
|
January 5, 2012
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
Kathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, et al.
Journal of Neuroendocrinology
|
December 14, 2023
Use and perceived utility of [<sup>18</sup> F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022
Valentina Ambrosini, Martyn Caplin, Justo P Castaño, et al.
Page
of 48